Barclays Starts Stocks in Medical Equipment Group: EW, COV, MDT, ZMH at Overweight, SYK, BCR at Underweight
More News related to BCR
- Morgan Keegan Starts BDX, HAE, BCR, MASI, COO at Outperform, BAX, HRC, COV, TFX, ISRG at Market Perform
- Bard to Host December 2009 Investor Conference
- CR Bard (BCR) Tops Q3 EPS by 3c
- Bard Announces Third Quarter Results
- Barclays Starts Stocks in Medical Equipment Group: EW, COV, MDT, ZMH at Overweight, SYK, BCR at Underweight
More News related to BSX
- Boston Scientific to Participate in Piper Jaffray Health Care Conference
- Boston Scientific (BSX) Receives 510(k) Clearance and CE Mark on WallFlex
- Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent
- UBS Upgrades Boston Scientific (BSX) to Buy
- Trading Review for Viking Systems Inc. Issued by Beacon Equity
More News related to COV
- Covidien to Present at Piper Jaffray Health Care Conference
- Covidien (COV) Announces FDA Extends Review of NDA for Exalgo
- FDA Extends Review of NDA for Exalgo(TM)
- Morgan Keegan Starts BDX, HAE, BCR, MASI, COO at Outperform, BAX, HRC, COV, TFX, ISRG at Market Perform
- Covidien (COV) Posts Q4 adj.-EPS of $0.72, Tops by 4c
Barclays has initiated coverage on numerous names in the Medical Equipment and Supplies sector this afternoon:
- Edwards Lifesciences (NYSE: EW) at Overweight with an $80 price target
- Covidien (NYSE: COV) at Overweight with a $57 price target
- Medtronic (NYSE: MDT) at Overweight with a $48 price target
- Zimmer Holdings (NYSE: ZMH) at Overweight with a $64 price target
- Boston Scientific (NYSE: BSX) at Equal Weight with a $12 price target
- St. Jude Medical (NYSE: STJ) at Equal Weight with a $40 price target
- NuVasive (Nasdaq: NUVA) at Equal Weight
- Thoratec (Nasdaq: THOR) at Equal Weight with a $35 price target
- Stryker (NYSE: SYK) at Underweight with a $44 price target
- CR Bard (NYSE: BCR) at Underweight with a $78 price target
Related Categories
New CoverageStocks Mentioned
-0.14
+0.06Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
